Sector News

J&J reportedly explores sale of $2 bln sterilization division

February 20, 2018
Life sciences

Johnson & Johnson is seeking buyers for its sterilization products division, as the health-care conglomerate continues to sell off non-core assets, Bloomberg reported citing people familiar with the matter.

J&J is working with an adviser to solicit bids for the unit, which could fetch as much as $2 billion, the report said. The asset is drawing interest from strategic buyers as well as private equity firms, the people said. Bids are due this week.

No final decision has been made and J&J may choose not to divest the division, the report said.

The advanced sterilization products unit, known as ASP, makes systems and solutions to clean medical tools. Its products, which are sold globally, include the Sterrad system for sterilizing instruments and Cidex OPA solution for disinfecting scopes.

Source: RTT News

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).